These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

615 related items for PubMed ID: 19221316

  • 1. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
    Olanow CW.
    Neurology; 2009 Feb 17; 72(7 Suppl):S59-64. PubMed ID: 19221316
    [Abstract] [Full Text] [Related]

  • 2. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease.
    Schapira AH.
    Neurology; 2009 Feb 17; 72(7 Suppl):S44-50. PubMed ID: 19221314
    [Abstract] [Full Text] [Related]

  • 3. Preclinical versus clinical neuroprotection.
    Grünblatt E, Schlösser R, Gerlach M, Riederer P.
    Adv Neurol; 2003 Feb 17; 91():309-28. PubMed ID: 12442689
    [No Abstract] [Full Text] [Related]

  • 4. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W.
    Neurology; 2009 Feb 17; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [Abstract] [Full Text] [Related]

  • 5. Treatment of levodopa-induced motor complications.
    Stocchi F, Tagliati M, Olanow CW.
    Mov Disord; 2008 Feb 17; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [Abstract] [Full Text] [Related]

  • 6. Why have we failed to achieve neuroprotection in Parkinson's disease?
    Olanow CW, Kieburtz K, Schapira AH.
    Ann Neurol; 2008 Dec 17; 64 Suppl 2():S101-10. PubMed ID: 19127580
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations.
    Bhidayasiri R, Ling H.
    J Med Assoc Thai; 2009 Jan 17; 92(1):142-54. PubMed ID: 19260256
    [Abstract] [Full Text] [Related]

  • 9. When and how should treatment be started in Parkinson disease?
    Lang AE.
    Neurology; 2009 Feb 17; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [Abstract] [Full Text] [Related]

  • 10. Treatment of early Parkinson's disease. Part 2.
    Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D.
    Eur Neurol; 2009 Feb 17; 61(4):206-15. PubMed ID: 19176961
    [Abstract] [Full Text] [Related]

  • 11. Early pharmacologic treatment in Parkinson's disease.
    Hauser RA.
    Am J Manag Care; 2010 Mar 17; 16 Suppl Implications():S100-7. PubMed ID: 20297870
    [Abstract] [Full Text] [Related]

  • 12. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ, Swope DM, Dashtipour K.
    Clin Ther; 2007 Sep 17; 29(9):1825-49. PubMed ID: 18035186
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.